PICC输注伊曲康唑注射液安全性研究

Safety study on infusion of PICC intraconazole injection

目的 探讨与常规输注方法 相比应用PICC输注伊曲康唑注射液的安全性,同时评估输注前后不同的回抽血量对输注效果的影响.方法选取2014年1月至2015年12月在血液科造血干细胞移植留观病房住院、通过外周静脉输注伊曲康唑注射液的患者32例作为对照组,选取同期在血液科造血干细胞移植留观病房住院、置有PICC、医嘱静脉输注伊曲康唑注射液的患者90例作为试验组,将试验组按随机数字表法分为3组,每组30例,试验组A、B、C分别回抽静脉血10.0、0.5、1.0 ml.在输注前抽取不同血量伊曲康唑疗程为10 d,比较10 d后各组导管堵塞和静脉炎的发生率.结果 无一例发生导管堵塞;对照组和试验组静脉炎发生率分别为21.9%(7/32)、0,差异有统计学意义(χ2=21.157,P<0.05),试验组各组比较差异无统计学意义(P>0.05).结论 回抽血量至针乳头即可满足治疗需求.经PICC输注伊曲康唑注射液,可有效避免该药物引起的导管堵塞;与外周输注相比,能显著降低静脉炎的发生率.

Objective To study the safety of transfusion of itraconazole through PICC and to evaluate the effect of different amount of blood transfusion before and after the infusion. Methods Patients were recruited from January 1, 2014, until December 31, 2015, in the Hematology hematopoietic stem cell transplantation ward. Thiry-two patients were recruited in the control group. Ninety patients wererecruited in the experience group. They were randomly assigned to three groups with 30 cases each, extracting different amounts of itraconazole before infusion, back phlebotomize in group A, B, C respectively was 10.0, 0.5, 1.0 ml. Comparing the phlebitis and obstruction after ten days from the transfusion day on. Results Catheter obstruction was not observed in any case. There was a significant difference between control group (21.9%,7/32) and observation group (0) regarding the incidence of phlebitis (χ2=21.157,P < 0.05). No statistical difference was noted among the observation groups regarding the incidence of phlebitis (P>0.05). Conclusions Drawing a small amount of blood volume before itraconazole injection through PICC can effectively avoid the drug-induced catheterobstruction. What′s more, transfusion through PICC can significantly reduce the incidence of phlebitis compared with peripheral infusion.